News
PHCUF
6.00
NaN%
--
Photocure’s BRAVO Study Highlights Cost-Effectiveness of Blue Light Cystoscopy
TipRanks · 12/08 07:34
Photocure ASA Study Highlights Economic Impact of Blue Light Cystoscopy in Europe
TipRanks · 11/19 07:36
Photocure ASA’s Earnings Call Highlights Growth and Innovation
TipRanks · 10/31 00:37
Photocure ASA Reports Strong Q3 2025 Growth
TipRanks · 10/30 04:58
Photocure ASA reports Q3 results
Seeking Alpha · 10/29 10:19
Photocure ASA Reports Strong Q3 2025 Performance and Strategic Partnership
TipRanks · 10/29 06:36
Photocure ASA’s AI-Enhanced Blue Light Cystoscopy: A New Era in Bladder Cancer Detection
TipRanks · 10/27 20:02
Photocure ASA Advances Bladder Cancer Treatment with Ongoing Study
TipRanks · 10/27 19:57
Photocure ASA to Announce Q3 2025 Financial Results
TipRanks · 10/24 06:38
Photocure Partners with ISC for AI-Enhanced Bladder Cancer Detection
Barchart · 10/16 11:46
Photocure ASA Grants Share Options to Employees Under Incentive Program
TipRanks · 09/22 06:34
Weekly Report: what happened at PHCUF last week (0908-0912)?
Weekly Report · 09/15 12:02
Weekly Report: what happened at PHCUF last week (0901-0905)?
Weekly Report · 09/08 12:04
Weekly Report: what happened at PHCUF last week (0825-0829)?
Weekly Report · 09/01 11:58
Weekly Report: what happened at PHCUF last week (0818-0822)?
Weekly Report · 08/25 12:13
Weekly Report: what happened at PHCUF last week (0811-0815)?
Weekly Report · 08/18 12:02
Weekly Report: what happened at PHCUF last week (0804-0808)?
Weekly Report · 08/11 12:12
Weekly Report: what happened at PHCUF last week (0728-0801)?
Weekly Report · 08/04 12:15
Photocure ASA Reports Strong Q2 2025 Growth
TipRanks · 07/31 04:52
More
Webull provides a variety of real-time PHCUF stock news. You can receive the latest news about Photocure ASA through multiple platforms. This information may help you make smarter investment decisions.
About PHCUF
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.